Search

Your search keyword '"Marvisi, C"' showing total 107 results

Search Constraints

Start Over You searched for: Author "Marvisi, C" Remove constraint Author: "Marvisi, C"
107 results on '"Marvisi, C"'

Search Results

1. POS0115 EOSINOPHILIC GIANT CELL ARTERITIS: A DIFFERENT SUBSET OF DISEASE?

2. POS0932 AORTIC INVOLVEMENT IN GCA: A MULTICENTER RETROSPECTIVE STUDY

4. AB1261 AVACOPAN IN THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS: MULTICENTER PROSPECTIVE REAL-LIFE STUDY ON EFFICACY, SAFETY, AND IMPACT ON QUALITY OF LIFE

9. Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospective Italian P-RHEUM.it study

10. Systemic vasculitis: one year in review 2024

12. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis

14. AB0771 FEMALE GENDER AND STEROID TREATMENT AS MAIN INFLUENCING FACTORS IN THE PERCEPTION OF QUALITY OF LIFE IN ANCA-ASSOCIATED VASCULITIS: FINAL RESULTS FROM THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE

15. POS0722 EFFECTS ON SOLUBLE IMMUNE CHECKPOINTS INDUCED BY TOCILIZUMAB MONOTHERAPY AFTER ULTRA-SHORT-TERM GLUCOCORTICOIDS IN LARGE VESSEL – GIANT CELL ARTERITIS PATIENTS

16. POS1176 HOSPITALIZATION RATES, FEATURES, AND DISCHARGE DIAGNOSES OF A LARGE NATIONWIDE COHORT OF ANCA-ASSOCIATED VASCULITIS

18. POS0711 DEVELOPMENT OF THE TAKAYASU’S ARTERITIS INTEGRATED DISEASE ACTIVITY INDEX

19. POS0728 EFFECTIVENESS AND SAFETY OF A 26 WEEK TAPER REGIMEN OF GLUCOCORTICOID IN NEWLY-DIAGNOSED GCA PATIENTS: A REAL LIFE EXPERIENCE

20. AB0723 TAKAYASU ARTERITIS AND LARGE-VESSEL GIANT CELL ARTERITIS IN ITALIAN POPULATION. A RETROSPECTIVE COHORT STUDY

21. POS0696 TREATMENT OF GIANT CELL ARTERITIS PATIENTS WITH ULTRA-SHORT GLUCOCORTICOIDS AND TOCILIZUMAB: ROLE OF IMAGING IN A PROSPECTIVE STUDY

22. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

23. Émulation d’un essai clinique comparant les corticoïdes versus les corticoïdes plus le cyclophosphamide au cours de la granulomatose éosinophilique avec polyangéite sévère

24. Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study

25. AB0627 Evaluation of internal consistency, feasibility, and reliability of the Italian version of ANCA-associated vasculitis patient-reported outcome (AAV-PRO_ita) questionnaire: preliminary results from a multicenter study on a large cohort of Italian patients

26. EVALUATION OF INTERNAL CONSISTENCY, FEASIBILITY, AND RELIABILITY OF THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE: PRELIMINARY RESULTS FROM A MULTICENTER STUDY ON A LARGE COHORT OF ITALIAN PATIENTS

27. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease

28. Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

29. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status

30. Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome)

31. Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

33. FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis

34. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status

35. PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS

36. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS

37. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status

38. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status

39. New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group

40. 117. Prediction of Long-Term Evolutionary Profiles in Eosinophilic Granulomatosis with Polyangiitis (Churg– Strauss) Based on Baseline and Follow-Up Characteristics

41. 354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS

42. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease

43. FEMALE GENDER AND STEROID TREATMENT AS MAIN INFLUENCING FACTORS IN THE PERCEPTION OF QUALITY OF LIFE IN ANCA-ASSOCIATED VASCULITIS: FINAL RESULTS FROM THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE

Catalog

Books, media, physical & digital resources